The DOI matches its Crossref record.
Plasminogen Activators and Matrix Metalloproteinases in Angiogenesis
Abstract
In the initial stages of capillary formation (angiogenesis) microvascular endothelial cells of preexisting blood vessels locally degrade the underlying basal lamina and invade into the stroma of the tissue to be vascularized. A consistent body of experimental evidence has shown that this process requires a wide array of dedradative enzymes. Components of the plasminogen activator (PA)-plasmin system and of the matrix metalloproteinase (MMP) family play important roles. PAs trigger a proteinase cascade that results is the generation of high local concentrations of plasmin and active MMPs. This increase in proteolytic activity has three major consequences: it permits endothelial cell degradation and invasion of the vessel basal lamina, generates extracellular matrix (ECM) degradation products that are chemotactic for endothelial cells, and activates and mobilizes growth factors localized in the ECM. In addition, urokinase-type PA modulates some endothelial cell functions, including proliferation and migration, with a mechanism independent of proteolytic activity. PA and MMP activities are modulated in endothelial cells by complex mechanisms, including transcriptional regulation by a variety of growth factors and cytokines with angiogenic activity, extracellular control of the proteolytic activities by tissue inhibitors, and interaction with binding sites on the cell membrane and ECM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Gehron Robey, P., Poole, A. R., Pidoux, I., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80064-1 · Cited by 1,298
Activity-based protein profiling: The serine hydrolases
Liu, Y., Patricelli, M. P., & Cravatt, B. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14694 · Cited by 1,133
Retinal ischemia: mechanisms of damage and potential therapeutic strategies
Osborne, N. N., Casson, R. J., Wood, J. P. M., Chidlow, G., Graham, M., & Melena, J. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.12.001 · Cited by 1,056
Vascular endothelial growth factors and angiogenesis in eye disease
Witmer, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00043-5 · Cited by 927
Matrix metalloproteinases in neuroinflammation
Rosenberg, G. A. (2002) · Glia · doi:10.1002/glia.10108 · Cited by 868
Matrix metalloproteinases in tumor invasion and metastasis
Stamenkovic, I. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0379 · Cited by 815
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Vascular Events After Spinal Cord Injury: Contribution to Secondary Pathogenesis
Mautes, A. E., Weinzierl, M. R., Donovan, F., & Noble, L. J. (2000) · Physical Therapy · doi:10.1093/ptj/80.7.673 · Cited by 405
Generation and degradation of human endostatin proteins by various proteinases
Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R., & Delaissé, J.-M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02249-3 · Cited by 377
Mathematical modeling of tumor-induced angiogenesis
Mantzaris, N. V., Webb, S., & Othmer, H. G. (2004) · Journal of Mathematical Biology · doi:10.1007/s00285-003-0262-2 · Cited by 362
Haas, T. L., Davis, S. J., & Madri, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3604 · Cited by 351
Mechanisms of inhibitors of mutagenesis and carcinogenesis
De Flora, S. (1998) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(97)00292-3 · Cited by 304
The Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors
Moses, M. A. (1997) · STEM CELLS · doi:10.1002/stem.150180 · Cited by 298
Sieczkiewicz, G. J., Hussain, M., & Kohn, E. C. (2002) · Ovarian Cancer · doi:10.1007/978-1-4757-3587-1_17 · Cited by 295
The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies
Smorenburg, S. M., & Van Noorden, C. J. F. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01481-9 · Cited by 294
Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types
DANØ, K., RØMER, J., NIELSEN, B. S., BJØRN, S., PYKE, C., RYGAARD, J., & LUND, L. R. (1999) · APMIS · doi:10.1111/j.1699-0463.1999.tb01534.x · Cited by 291
Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis
Stephens, R. W. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.869 · Cited by 279
Mohan, R., Sivak, J., Ashton, P., Russo, L. A., Pham, B. Q., Kasahara, N., Raizman, M. B., & Fini, M. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10405 · Cited by 274
Functional overlap between two classes of matrix-degrading proteases in wound healing
Lund, L. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4645 · Cited by 270
Angiogenesis and Its Therapeutic Opportunities
Yoo, S. Y., & Kwon, S. M. (2013) · Mediators of Inflammation · doi:10.1155/2013/127170 · Cited by 259
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Angiogenesis, adipokines and breast cancer
Vona-Davis, L., & Rose, D. P. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.05.007 · Cited by 148
Monea, S., Jordan, B. A., Srivastava, S., DeSouza, S., & Ziff, E. B. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3521-05.2006 · Cited by 104
Metadata
- Authors
- Mignatti, P., & Rifkin, D. B.
- Venue
- Enzyme and Protein
- Publisher
- S. Karger AG
- Published
- 1996
- Volume
- 49
- Issue
- 1-3
- Pages
- 117-137
- ISSN
- 1019-6773 (ISSN-L)
- 2504-2556
- OpenAlex
- W2396086641
- Cited by
- 330
- References
- 0
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.